Prevalence of smoldering multiple myeloma based on nationwide screening.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
07
07
2022
accepted:
13
12
2022
pubmed:
8
2
2023
medline:
25
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma. Here we define the epidemiological characteristics of SMM in the general population in Iceland. The iStopMM study (ClinicalTrials.gov ID: NCT03327597 ) is a nationwide screening study for multiple myeloma precursors where all residents in Iceland 40 years or older were invited to participate. SMM was defined as 10-60% bone marrow plasma cells and/or monoclonal (M) protein concentration ≥3 g dl
Identifiants
pubmed: 36747117
doi: 10.1038/s41591-022-02183-6
pii: 10.1038/s41591-022-02183-6
doi:
Banques de données
ClinicalTrials.gov
['NCT03327597']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-472Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Kyle, R. A. & Greipp, P. R. Smoldering multiple myeloma. N. Engl. J. Med. 302, 1347–1349 (1980).
doi: 10.1056/NEJM198006123022405
pubmed: 7374679
Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).
doi: 10.1056/NEJMoa070389
pubmed: 17582068
Kristinsson, S. Y., Holmberg, E. & Blimark, C. Treatment for high-risk smoldering myeloma. N. Engl. J. Med. 369, 1762–1763 (2013).
doi: 10.1056/NEJMc1310911
pubmed: 24171527
Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221–1227 (2018).
doi: 10.1001/jamaoncol.2018.2128
pubmed: 29800065
pmcid: 6143021
Kyle, R. A. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24, 1121–1127 (2010).
doi: 10.1038/leu.2010.60
pubmed: 20410922
pmcid: 7020664
Pérez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586–2592 (2007).
doi: 10.1182/blood-2007-05-088443
pubmed: 17576818
Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785–789 (2008).
doi: 10.1182/blood-2007-08-108357
pubmed: 17942755
pmcid: 2200851
Mateos, M.-V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).
doi: 10.1038/s41408-020-00366-3
pubmed: 33067414
pmcid: 7567803
Rajkumar, S. V., Landgren, O. & Mateos, M.-V. Smoldering multiple myeloma. Blood 125, 3069–3075 (2015).
doi: 10.1182/blood-2014-09-568899
pubmed: 25838344
pmcid: 4432003
Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).
doi: 10.1038/s41408-018-0077-4
pubmed: 29895887
pmcid: 5997745
Mateos, M.-V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
doi: 10.1056/NEJMoa1300439
pubmed: 23902483
Mateos, M.-V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127–1136 (2016).
doi: 10.1016/S1470-2045(16)30124-3
pubmed: 27402145
Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126–1137 (2020).
doi: 10.1200/JCO.19.01740
pubmed: 31652094
Kumar, S. K. et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 18, 1685–1717 (2020).
doi: 10.6004/jnccn.2020.0057
pubmed: 33285522
Lonial, S., Rajkumar, S. V. & Mateos, M. V. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. Lancet Haematol. 9, e162–e165 (2022).
doi: 10.1016/S2352-3026(21)00335-5
pubmed: 35114153
Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 1, 168–174 (2015).
doi: 10.1001/jamaoncol.2015.23
pubmed: 26181017
Go, R. S., Gundrum, J. D. & Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.Clin. Lymphoma Myeloma Leuk. 15, 177–186.e4 (2015).
doi: 10.1016/j.clml.2014.09.004
pubmed: 25445471
Rögnvaldsson, S. et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 11, 94 (2021).
doi: 10.1038/s41408-021-00480-w
pubmed: 34001889
pmcid: 8128921
Sørrig, R. et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur. J. Haematol. 97, 303–309 (2016).
doi: 10.1111/ejh.12728
pubmed: 26710662
Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241–249 (2018).
doi: 10.1056/NEJMoa1709974
pubmed: 29342381
pmcid: 5852672
Miguel, J. S. et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J. Clin. Oncol. 37, 8000 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.8000
Hill, E. et al. Assessment of discordance among smoldering multiple myeloma risk models. JAMA Oncol. 7, 132–134 (2021).
doi: 10.1001/jamaoncol.2020.5585
pubmed: 33211080
Maura, F. et al. Moving from cancer burden to cancer genomics for smoldering myeloma: a review. JAMA Oncol. 6, 425–432 (2019).
doi: 10.1001/jamaoncol.2019.4659
Maura, F., Landgren, O. & Morgan, G. J. Designing evolutionary based interception strategies to block the transition from precursor phases to multiple myeloma. Clin. Cancer Res. 27, 15–23 (2021).
doi: 10.1158/1078-0432.CCR-20-1395
pubmed: 32759358
Landgren, O. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Hematology Am. Soc. Hematol. Educ. Program 2021, 662–672 (2021).
doi: 10.1182/hematology.2021000303
pubmed: 34889381
pmcid: 8791104
Landgren, O. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468–1473 (2007).
doi: 10.1016/S0025-6196(11)61089-6
pubmed: 18053453
Iwanaga, M., Tagawa, M., Tsukasaki, K., Kamihira, S. & Tomonaga, M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin. Proc. 82, 1474–1479 (2007).
doi: 10.1016/S0025-6196(11)61090-2
pubmed: 18053454
Dimopoulos, M. A., Kastritis, E. & Terpos, E. Non-secretory myeloma: one, two, or more entities? Oncology 27, 930–932 (2013).
pubmed: 24282994
Mohyuddin, G. R., Ouchveridze, E., Goodman, A. & Prasad, V. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk. Lymphoma 62, 2793–2795 (2021).
doi: 10.1080/10428194.2021.1938032
pubmed: 34114943
Musto, P. et al. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica 106, 2799–2812 (2021).
doi: 10.3324/haematol.2021.278519
pubmed: 34261295
pmcid: 8561280
Kapoor, P. & Rajkumar, S. V. Smoldering multiple myeloma: to treat or not to treat. Cancer J. 25, 65–71 (2019).
doi: 10.1097/PPO.0000000000000350
pubmed: 30694862
Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094–2103 (2017).
doi: 10.1038/leu.2017.29
pubmed: 28104919
pmcid: 5629369